McGinn Penninger Investment Management Inc. Boosts Holdings in Merck & Co., Inc. $MRK

McGinn Penninger Investment Management Inc. lifted its position in shares of Merck & Co., Inc. (NYSE:MRK) by 33.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 46,781 shares of the company’s stock after acquiring an additional 11,666 shares during the quarter. Merck & Co., Inc. accounts for approximately 2.3% of McGinn Penninger Investment Management Inc.’s investment portfolio, making the stock its 20th biggest holding. McGinn Penninger Investment Management Inc.’s holdings in Merck & Co., Inc. were worth $3,703,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Little House Capital LLC grew its holdings in Merck & Co., Inc. by 1.2% during the 2nd quarter. Little House Capital LLC now owns 25,236 shares of the company’s stock valued at $1,998,000 after buying an additional 308 shares in the last quarter. Semus Wealth Partners LLC grew its holdings in shares of Merck & Co., Inc. by 8.2% during the first quarter. Semus Wealth Partners LLC now owns 5,039 shares of the company’s stock worth $452,000 after purchasing an additional 382 shares in the last quarter. Longfellow Investment Management Co. LLC boosted its stake in Merck & Co., Inc. by 20.4% in the first quarter. Longfellow Investment Management Co. LLC now owns 19,376 shares of the company’s stock worth $1,739,000 after buying an additional 3,282 shares in the last quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH boosted its stake in Merck & Co., Inc. by 9.8% in the second quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH now owns 888,415 shares of the company’s stock worth $70,327,000 after buying an additional 79,529 shares in the last quarter. Finally, Amplius Wealth Advisors LLC lifted its position in Merck & Co., Inc. by 117.4% in the second quarter. Amplius Wealth Advisors LLC now owns 6,165 shares of the company’s stock valued at $488,000 after purchasing an additional 3,329 shares during the last quarter. 76.07% of the stock is owned by hedge funds and other institutional investors.

Merck & Co., Inc. Trading Down 4.0%

Shares of NYSE:MRK opened at $82.51 on Tuesday. Merck & Co., Inc. has a 12-month low of $73.31 and a 12-month high of $105.07. The business’s fifty day simple moving average is $84.51 and its 200-day simple moving average is $81.89. The company has a market capitalization of $206.09 billion, a PE ratio of 12.71, a P/E/G ratio of 0.95 and a beta of 0.37. The company has a current ratio of 1.42, a quick ratio of 1.17 and a debt-to-equity ratio of 0.69.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Thursday, October 30th. The company reported $2.58 earnings per share for the quarter, topping the consensus estimate of $2.36 by $0.22. The firm had revenue of $17.28 billion for the quarter, compared to the consensus estimate of $17 billion. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%.The firm’s revenue for the quarter was up 3.7% on a year-over-year basis. During the same period in the previous year, the business earned $1.57 EPS. Merck & Co., Inc. has set its FY 2025 guidance at 8.930-8.980 EPS. As a group, equities research analysts predict that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently commented on MRK shares. Weiss Ratings restated a “hold (c-)” rating on shares of Merck & Co., Inc. in a report on Wednesday, October 8th. Morgan Stanley increased their price objective on shares of Merck & Co., Inc. from $98.00 to $100.00 and gave the company an “equal weight” rating in a research report on Monday. Wells Fargo & Company dropped their price objective on Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 30th. Berenberg Bank downgraded Merck & Co., Inc. from a “buy” rating to a “hold” rating and lowered their target price for the company from $100.00 to $90.00 in a report on Wednesday, September 17th. Finally, Citigroup assumed coverage on Merck & Co., Inc. in a research report on Monday, October 13th. They set a “neutral” rating and a $95.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $104.47.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.